venBio Partners LLC Long-Term Concentrated

CIK: 0001776382 · Show all filings

Period: Q1 2020 (← Previous) (Next →)

Filing Date: May 15, 2020

Total Value ($000): $117,344 (100.0% shares, 0.0% debt)

Holdings (6)

— AKERO THERAPEUTICS INC 56.9%

Value ($000) $66,780 Shares 3,150,019 Est. Cost $19.15 Unrealized —

— PRECISION BIOSCIENCES INC 20.6%

Value ($000) $24,168 Shares 4,007,901 Est. Cost $17.95 Unrealized —

APLS APELLIS PHARMACEUTICALS INC 11.5%

Value ($000) $13,437 Shares 501,584 Est. Cost $15.34 Unrealized +131.4%

— TURNING POINT THERAPEUTICS I 6.1%

Value ($000) $7,160 Shares 160,333 Est. Cost $40.70 Unrealized —

— MENLO THERAPEUTICS INC 3.3%

Value ($000) $3,917 Shares 1,461,552 Est. Cost $4.12 Unrealized —

— VERONA PHARMA PLC 1.6%

Value ($000) $1,882 Shares 456,770 Est. Cost $9.65 Unrealized —

Ticker	Issuer	Shares	Value ($000)	%	Est. Cost	Unrealized	Class	CUSIP
—	AKERO THERAPEUTICS INC	3,150,019	$66,780	56.9%	$19.15	—	COM	00973Y108
—	PRECISION BIOSCIENCES INC	4,007,901	$24,168	20.6%	$17.95	—	COM	74019P108
APLS	APELLIS PHARMACEUTICALS INC	501,584	$13,437	11.5%	$15.34	+131.4%	COM	03753U106
—	TURNING POINT THERAPEUTICS I	160,333	$7,160	6.1%	$40.70	—	COM	90041T108
—	MENLO THERAPEUTICS INC	1,461,552	$3,917	3.3%	$4.12	—	COM	586858102
—	VERONA PHARMA PLC	456,770	$1,882	1.6%	$9.65	—	SPONSORED ADS	925050106